Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial

Khalil Ibrahim, Rakesh R. Goli, Rohan Shah, Jon R. Resar, Steven P. Schulman, John W. McEvoy

Research output: Contribution to journalArticle

Abstract

Introduction Morphine reduces and delays the absorption of oral P2Y12 platelet inhibitors. Fentanyl is another opiate often administered during percutaneous coronary interventions (PCI). The PACIFY study will test whether intravenous fentanyl also impairs the absorption and action of oral P2Y12 inhibitors. Methods PACIFY is a single-center trial randomizing adults undergoing clinically-indicated coronary angiography to have the procedure with or without fentanyl. All patients will receive local anesthetic and intravenous midazolam. Doses of all drugs are at the discretion of treating providers. Patients that require PCI receive 180 mg of oral ticagrelor during the angiography procedure. The primary outcome is area under the ticagrelor plasma concentration-time curve. Secondary outcomes include platelet inhibition 2-h after loading, measured both by VerifyNow® (Accriva Diagnostics, San Diego, California) and by light-transmission platelet aggregometry. We will also survey patient comfort and measure high-sensitivity troponin levels. Patients and outcomes assessors are blinded, treating providers are not. Results A total of 212 patients are participating, 70 of whom required PCI. Baseline characteristics are numerically well balanced in both study arms. Mean age is 63 years and 27% are female. There were no differences in total midazolam dose during the index PCI procedure, whereas mean total fentanyl dose was 9 mcg in the no-fentanyl arm (2 participants in this arm required fentanyl for bailout treatment of pain) versus 96 mcg in the fentanyl arm. Conclusions This study will provide important information on the impact of fentanyl administered during PCI on the absorption of ticagrelor and its antiplatelet activity. Trial Registration: clinicaltrials.gov Identifier: NCT02683707.

LanguageEnglish (US)
Pages8-12
Number of pages5
JournalContemporary Clinical Trials
Volume64
DOIs
StatePublished - Jan 1 2018

Fingerprint

Fentanyl
Percutaneous Coronary Intervention
Blood Platelets
Midazolam
Opiate Alkaloids
Troponin
Inhibition (Psychology)
Ticagrelor
Platelet Aggregation Inhibitors
Local Anesthetics
Coronary Angiography
Morphine
Angiography
Light
Pain
Pharmaceutical Preparations

Keywords

  • Fentanyl
  • PCI
  • Pharmacodynamics
  • Pharmacokinetics
  • Platelet inhibition
  • Ticagrelor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{866acb4d9f8c4432b8eff3a4763558e9,
title = "Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial",
abstract = "Introduction Morphine reduces and delays the absorption of oral P2Y12 platelet inhibitors. Fentanyl is another opiate often administered during percutaneous coronary interventions (PCI). The PACIFY study will test whether intravenous fentanyl also impairs the absorption and action of oral P2Y12 inhibitors. Methods PACIFY is a single-center trial randomizing adults undergoing clinically-indicated coronary angiography to have the procedure with or without fentanyl. All patients will receive local anesthetic and intravenous midazolam. Doses of all drugs are at the discretion of treating providers. Patients that require PCI receive 180 mg of oral ticagrelor during the angiography procedure. The primary outcome is area under the ticagrelor plasma concentration-time curve. Secondary outcomes include platelet inhibition 2-h after loading, measured both by VerifyNow\{circledR} (Accriva Diagnostics, San Diego, California) and by light-transmission platelet aggregometry. We will also survey patient comfort and measure high-sensitivity troponin levels. Patients and outcomes assessors are blinded, treating providers are not. Results A total of 212 patients are participating, 70 of whom required PCI. Baseline characteristics are numerically well balanced in both study arms. Mean age is 63 years and 27\{%} are female. There were no differences in total midazolam dose during the index PCI procedure, whereas mean total fentanyl dose was 9 mcg in the no-fentanyl arm (2 participants in this arm required fentanyl for bailout treatment of pain) versus 96 mcg in the fentanyl arm. Conclusions This study will provide important information on the impact of fentanyl administered during PCI on the absorption of ticagrelor and its antiplatelet activity. Trial Registration: clinicaltrials.gov Identifier: NCT02683707.",
keywords = "Fentanyl, PCI, Pharmacodynamics, Pharmacokinetics, Platelet inhibition, Ticagrelor",
author = "Khalil Ibrahim and Goli, {Rakesh R.} and Rohan Shah and Resar, {Jon R.} and Schulman, {Steven P.} and McEvoy, {John W.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cct.2017.11.011",
language = "English (US)",
volume = "64",
pages = "8--12",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention

T2 - Contemporary Clinical Trials

AU - Ibrahim,Khalil

AU - Goli,Rakesh R.

AU - Shah,Rohan

AU - Resar,Jon R.

AU - Schulman,Steven P.

AU - McEvoy,John W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction Morphine reduces and delays the absorption of oral P2Y12 platelet inhibitors. Fentanyl is another opiate often administered during percutaneous coronary interventions (PCI). The PACIFY study will test whether intravenous fentanyl also impairs the absorption and action of oral P2Y12 inhibitors. Methods PACIFY is a single-center trial randomizing adults undergoing clinically-indicated coronary angiography to have the procedure with or without fentanyl. All patients will receive local anesthetic and intravenous midazolam. Doses of all drugs are at the discretion of treating providers. Patients that require PCI receive 180 mg of oral ticagrelor during the angiography procedure. The primary outcome is area under the ticagrelor plasma concentration-time curve. Secondary outcomes include platelet inhibition 2-h after loading, measured both by VerifyNow® (Accriva Diagnostics, San Diego, California) and by light-transmission platelet aggregometry. We will also survey patient comfort and measure high-sensitivity troponin levels. Patients and outcomes assessors are blinded, treating providers are not. Results A total of 212 patients are participating, 70 of whom required PCI. Baseline characteristics are numerically well balanced in both study arms. Mean age is 63 years and 27% are female. There were no differences in total midazolam dose during the index PCI procedure, whereas mean total fentanyl dose was 9 mcg in the no-fentanyl arm (2 participants in this arm required fentanyl for bailout treatment of pain) versus 96 mcg in the fentanyl arm. Conclusions This study will provide important information on the impact of fentanyl administered during PCI on the absorption of ticagrelor and its antiplatelet activity. Trial Registration: clinicaltrials.gov Identifier: NCT02683707.

AB - Introduction Morphine reduces and delays the absorption of oral P2Y12 platelet inhibitors. Fentanyl is another opiate often administered during percutaneous coronary interventions (PCI). The PACIFY study will test whether intravenous fentanyl also impairs the absorption and action of oral P2Y12 inhibitors. Methods PACIFY is a single-center trial randomizing adults undergoing clinically-indicated coronary angiography to have the procedure with or without fentanyl. All patients will receive local anesthetic and intravenous midazolam. Doses of all drugs are at the discretion of treating providers. Patients that require PCI receive 180 mg of oral ticagrelor during the angiography procedure. The primary outcome is area under the ticagrelor plasma concentration-time curve. Secondary outcomes include platelet inhibition 2-h after loading, measured both by VerifyNow® (Accriva Diagnostics, San Diego, California) and by light-transmission platelet aggregometry. We will also survey patient comfort and measure high-sensitivity troponin levels. Patients and outcomes assessors are blinded, treating providers are not. Results A total of 212 patients are participating, 70 of whom required PCI. Baseline characteristics are numerically well balanced in both study arms. Mean age is 63 years and 27% are female. There were no differences in total midazolam dose during the index PCI procedure, whereas mean total fentanyl dose was 9 mcg in the no-fentanyl arm (2 participants in this arm required fentanyl for bailout treatment of pain) versus 96 mcg in the fentanyl arm. Conclusions This study will provide important information on the impact of fentanyl administered during PCI on the absorption of ticagrelor and its antiplatelet activity. Trial Registration: clinicaltrials.gov Identifier: NCT02683707.

KW - Fentanyl

KW - PCI

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Platelet inhibition

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=85034808952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034808952&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2017.11.011

DO - 10.1016/j.cct.2017.11.011

M3 - Article

VL - 64

SP - 8

EP - 12

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -